Dorzolamide

When using the drug Dorzolamide-SOLOpharm, the usual dosage is 1 drop to the affected eye (or both eyes) in the morning, afternoon and evening.

If you replace any antiglaucoma drug with Dorzolamide-SOLOpharm, you should start treatment with Dorzolamide-SOLOpharm from the day after the previous drug is canceled.

With simultaneous use of the drug Dorzolamide-SOLOpharm with other eye drops, they should be instilled with an interval of at least 10 minutes.

The procedure for working with a drip tube:

1. Separate one tube-dropper.

2. Open the tube-dropper (making sure that the solution is in the lower part of the tube-dropper, turn the rotating movements and separate the valve).

3. Instill the required amount of the drug in the eye.

The dose contained in the tube-dropper is sufficient for one instillation in both eyes. After a single use, the dropper tube should be discarded, even if the contents remain.

Adverse reactions

In clinical trials, the drug with dorzolamide in the form of eye drops was administered to 1108 patients as monotherapy or additional therapy to treatment with beta-blockers. In approximately 3% of patients, the drug was canceled due to local adverse reactions from the side of the eye, the most frequent of which were conjunctivitis and the reaction of the eyelids.

The side effects recorded during the research and during the post-registration period are classified by frequency (very often (≥1 / 10); often (≥1 / 100.1 / 10000,

The nervous system

Often: headache.

Seldom: dizziness, paresthesias.

On the part of the organ of vision

Very often: burning and pain.

Often: superficial point keratitis, lacrimation, conjunctivitis, inflammation of the eyelids, itching, irritation of the century, blurred vision.

Infrequently: iridocyclitis.

Rarely: eye redness, pain, hyperkeratosis of the eyelids, transient myopia (disappearing after drug withdrawal), corneal edema, decrease in intraocular pressure, detachment of the choroidal membrane of the eye after surgical interventions to restore the outflow of intraocular fluid.

On the part of the respiratory system,chest and mediastinum

Rarely: nosebleeds.

From the gastrointestinal tract

Often: nausea, bitter taste in the mouth.

Rarely: pharyngitis, dry mouth.

From the urinary tract

Rarely: urolithiasis.

From the skin and subcutaneous tissue

Seldom: contact dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis.

General disorders and disorders at the site of administration

Often: asthenia, fatigue.

Rarely: allergic reactions - signs and symptoms of local reactions (from the eyelids) and systemic allergic reactions, including angioedema, urticaria, pruritus, rash, difficulty breathing, less often - bronchospasm.

Children

During a 3-month double-blind multicenter study using the active drug as a control, conducted with 184 children under the age of 6 years, the adverse reaction profile of the drug with dorzolamide in the form of eye drops was comparable to the profile of adverse reactions in adult patients. The most frequent adverse reactions associated with the use of the drug with dorzolamide in the form of eye drops in children under the age of 2 years were conjunctival injection (5.4%) and discharge from the eyes (3.6%). In children from 2 to 6 years old, the most frequent adverse reactions were burning sensation in the eye (12.1%), conjunctival injection (7.6%), eye pain (3%), and inflammation of the eyelids (3%).

Contraindications

- Age less than 1 week;

- hypersensitivity to the drug;

- chronic renal failure;

- pregnancy;

- breastfeeding period.

Carefully:

The drug has not been studied in patients with severe liver failure and, therefore, should be used in this category of patients with caution.

Drug interactions

Special studies on the interaction of the drug Dorzolamide-SOLOpharm with other drugs have not been conducted. In clinical studies, a drug with dorzolamide in the form of eye drops was prescribed in combination with other drugs without negative manifestations of drug-free interaction, including: with eye drops of timolol and betaxolol, as well as systemic drugs: inhibitors of angiotensin-converting enzyme (ACF), calcium channel blockers, diuretics , nonsteroidal anti-inflammatory drugs (including acetylsalicylic acid), hormones (estrogen, insulin, thyroxin).

The possibility of mutual enhancement of the systemic effects of carbonic anhydrase inhibitors for internal use and the drug Dorzolamide-SOLOpharm with their simultaneous use is not excluded. Combined treatment with drugs that have a systemic effect and local carbonic anhydrase inhibitors has not been studied in clinical studies.

Dorzolamide-SOLOpharm is a carbonic anhydrase inhibitor, and although it is applied topically, it is partially absorbed and can have a systemic effect. In clinical studies, the use of drugs with dorzolamide in the form of eye drops was not accompanied by a violation of the acid-base balance. However, similar phenomena were observed with the use of carbonic anhydrase inhibitors, including as a result of interactions with other drugs (as a manifestation of toxicity in patients receiving high doses of salicylates). Thus, when administering the drug Dorzolamide-SOLOpharm, one should not forget about the possibility of such interdrug interactions.

The patient should inform the doctor about all medicines that he uses or plans to use, including those that are sold without a prescription.

Special attention should be paid to taking high doses of acetylsalicylic acid, since toxicity may increase.

Pregnancy and Lactation

Special instructions

Overdosage